StockNews.com initiated coverage on shares of Prothena (NASDAQ:PRTA – Get Rating) in a research report released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Several other research firms also recently weighed in on PRTA. Citigroup decreased their price target on shares of Prothena from $76.00 to $72.00 and set […]
Shares of Prothena Co. plc (NASDAQ:PRTA – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month […]
Prothena (NASDAQ:PRTA – Get Rating) had its target price increased by HC Wainwright from $75.00 to $90.00 in a report released on Friday, The Fly reports. A number of other equities analysts have also recently issued reports on the company. SVB Securities began coverage on Prothena in a report on Monday, April 24th. They issued […]
Prothena Co. plc (NASDAQ:PRTA – Get Rating) Director Dennis J. Selkoe sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $57.00, for a total value of $855,000.00. Following the completion of the transaction, the director now directly owns 2,845 shares in […]
Brokerages forecast that Prothena Co. plc (NASDAQ:PRTA – Get Rating) will post earnings of ($0.85) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Prothena’s earnings, with estimates ranging from ($0.94) to ($0.78). Prothena reported earnings of ($0.91) per share during the same quarter last year, which suggests a […]